JP2017537888A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537888A5 JP2017537888A5 JP2017522654A JP2017522654A JP2017537888A5 JP 2017537888 A5 JP2017537888 A5 JP 2017537888A5 JP 2017522654 A JP2017522654 A JP 2017522654A JP 2017522654 A JP2017522654 A JP 2017522654A JP 2017537888 A5 JP2017537888 A5 JP 2017537888A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- fusion protein
- seq
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000037865 fusion proteins Human genes 0.000 claims 30
- 108020001507 fusion proteins Proteins 0.000 claims 30
- 108090000765 processed proteins & peptides Proteins 0.000 claims 30
- 229920001184 polypeptide Polymers 0.000 claims 28
- 102000004196 processed proteins & peptides Human genes 0.000 claims 28
- 125000003275 alpha amino acid group Chemical group 0.000 claims 15
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims 12
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 108060003951 Immunoglobulin Proteins 0.000 claims 6
- 102000008847 Serpin Human genes 0.000 claims 6
- 108050000761 Serpin Proteins 0.000 claims 6
- 229940024142 alpha 1-antitrypsin Drugs 0.000 claims 6
- 102000018358 immunoglobulin Human genes 0.000 claims 6
- 208000027866 inflammatory disease Diseases 0.000 claims 6
- 208000015181 infectious disease Diseases 0.000 claims 5
- 101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 102000009027 Albumins Human genes 0.000 claims 2
- 108010088751 Albumins Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 102000007562 Serum Albumin Human genes 0.000 claims 2
- 108010071390 Serum Albumin Proteins 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 102000051631 human SERPINA1 Human genes 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 206010053555 Arthritis bacterial Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 208000004575 Infectious Arthritis Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 102000012479 Serine Proteases Human genes 0.000 claims 1
- 108010022999 Serine Proteases Proteins 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 230000001594 aberrant effect Effects 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000001223 septic arthritis Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/524,832 | 2014-10-27 | ||
| US14/524,832 US10400029B2 (en) | 2011-06-28 | 2014-10-27 | Serpin fusion polypeptides and methods of use thereof |
| PCT/US2015/057533 WO2016069574A1 (en) | 2014-10-27 | 2015-10-27 | Serpin fusion polypeptides and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020121953A Division JP2020180157A (ja) | 2014-10-27 | 2020-07-16 | セルピン融合ポリペプチド及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017537888A JP2017537888A (ja) | 2017-12-21 |
| JP2017537888A5 true JP2017537888A5 (enExample) | 2018-10-25 |
| JP6737781B2 JP6737781B2 (ja) | 2020-08-12 |
Family
ID=55858243
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017522654A Active JP6737781B2 (ja) | 2014-10-27 | 2015-10-27 | セルピン融合ポリペプチド及びその使用方法 |
| JP2020121953A Pending JP2020180157A (ja) | 2014-10-27 | 2020-07-16 | セルピン融合ポリペプチド及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020121953A Pending JP2020180157A (ja) | 2014-10-27 | 2020-07-16 | セルピン融合ポリペプチド及びその使用方法 |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP3212290A4 (enExample) |
| JP (2) | JP6737781B2 (enExample) |
| KR (2) | KR20240005109A (enExample) |
| CN (2) | CN114316068A (enExample) |
| AU (3) | AU2015339507B2 (enExample) |
| BR (1) | BR112017008525A2 (enExample) |
| CA (1) | CA2965151A1 (enExample) |
| HK (1) | HK1244460A1 (enExample) |
| IL (2) | IL251799B2 (enExample) |
| MX (2) | MX2017005467A (enExample) |
| NZ (1) | NZ769391A (enExample) |
| RU (1) | RU2746550C2 (enExample) |
| SG (2) | SG10201903142RA (enExample) |
| UA (1) | UA127305C2 (enExample) |
| WO (1) | WO2016069574A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113286816B (zh) * | 2018-10-29 | 2025-04-04 | 斯宾疗法有限责任公司 | 用于α-1-抗胰蛋白酶病症的组合物和方法 |
| WO2020097946A1 (zh) * | 2018-11-18 | 2020-05-22 | 杭州博虎生物科技有限公司 | 一种重组人白细胞介素10融合蛋白及其应用 |
| CN112315897A (zh) * | 2020-11-04 | 2021-02-05 | 深圳前海鹰岗生物科技有限公司 | 一种抑制细胞炎症反应释放治疗痛风急性发作的聚合物微针及制备方法 |
| WO2022133521A1 (en) * | 2020-12-21 | 2022-06-30 | Macquarie University | Treatment of glaucoma |
| GB202102258D0 (en) * | 2021-02-17 | 2021-03-31 | Arecor Ltd | Novel composition |
| MX2023009921A (es) * | 2021-03-03 | 2023-09-05 | Formycon Ag | Formulaciones de proteinas de fusion ace2-fc. |
| CN113325181A (zh) * | 2021-04-25 | 2021-08-31 | 苏州市立医院(北区) | 丝氨酸蛋白酶抑制剂在用于脓毒症早期预警的标志物中的应用 |
| CN119638849A (zh) * | 2021-10-18 | 2025-03-18 | 深圳科兴药业有限公司 | 一种生长激素融合蛋白及其应用 |
| IL316983A (en) | 2022-05-16 | 2025-01-01 | Sanofi Aatd Inc | Effective dosage of recombinant SERPIN-FC fusion protein for use in a method of treating AAT deficiency in a subject |
| CN121100127A (zh) * | 2023-05-05 | 2025-12-09 | 保罗·托马斯·金 | 新型治疗性多肽 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002537810A (ja) * | 1999-03-01 | 2002-11-12 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | ヒトセルピンタンパク質 |
| US7317091B2 (en) * | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US7217797B2 (en) * | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| CA2532664A1 (en) * | 2003-07-18 | 2005-01-27 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| EP3192872A1 (en) * | 2003-08-26 | 2017-07-19 | The Regents of the University of Colorado, a body corporate | Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections |
| JP4652414B2 (ja) * | 2004-11-12 | 2011-03-16 | ゼンコー・インコーポレイテッド | ＦｃＲｎとの変化した結合を有するＦｃ変異体 |
| US8802820B2 (en) * | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| EP1910542B1 (en) * | 2005-07-22 | 2009-12-02 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with fgfr fusion proteins |
| CA2618951A1 (en) * | 2005-08-12 | 2007-02-22 | Schering Corporation | Mcp1 fusions |
| AU2009262199B2 (en) * | 2008-06-27 | 2012-08-09 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
| EP3482769B1 (en) * | 2008-12-19 | 2024-05-29 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| HUE033205T2 (en) * | 2010-12-23 | 2017-11-28 | Janssen Biotech Inc | Active protease-resistant antibody fc mutants |
| HRP20181690T4 (hr) * | 2011-03-29 | 2025-01-03 | Roche Glycart Ag | Varijante protutijela fc |
| SG10201601621PA (en) * | 2011-06-28 | 2016-04-28 | Inhibrx Llc | Serpin fusion polypeptides and methods of use thereof |
| WO2013003649A2 (en) * | 2011-06-28 | 2013-01-03 | Inhibrx Llc | Wap domain fusion polypeptides and methods of use thereof |
| WO2013106589A1 (en) * | 2012-01-10 | 2013-07-18 | The Regents Of The University Of Colorado, A Body Corporate | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
| CA2877363A1 (en) * | 2012-06-21 | 2013-12-27 | Indiana University Research And Technology Corporation | Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function |
| BR112014028368A2 (pt) * | 2012-06-27 | 2017-11-14 | Hoffmann La Roche | método de produção de conjugado de região fc de anticorpo, conjugado de região fc de anticorpo e formulação farmacêutica |
| HUE029634T2 (en) * | 2012-08-02 | 2017-03-28 | Hoffmann La Roche | A method for producing soluble FcR as an Fc fusion with an inert immunoglobulin Fc region and its uses |
| WO2014089375A1 (en) * | 2012-12-05 | 2014-06-12 | Boston Strategics Corporation | Protein expression enhancing polypeptides |
-
2015
- 2015-10-27 CN CN202111439584.9A patent/CN114316068A/zh active Pending
- 2015-10-27 SG SG10201903142RA patent/SG10201903142RA/en unknown
- 2015-10-27 KR KR1020237043666A patent/KR20240005109A/ko not_active Ceased
- 2015-10-27 RU RU2017118325A patent/RU2746550C2/ru active
- 2015-10-27 IL IL251799A patent/IL251799B2/en unknown
- 2015-10-27 WO PCT/US2015/057533 patent/WO2016069574A1/en not_active Ceased
- 2015-10-27 BR BR112017008525-9A patent/BR112017008525A2/pt active Search and Examination
- 2015-10-27 CN CN201580071331.7A patent/CN107206257A/zh active Pending
- 2015-10-27 NZ NZ769391A patent/NZ769391A/en unknown
- 2015-10-27 MX MX2017005467A patent/MX2017005467A/es unknown
- 2015-10-27 SG SG11201703390SA patent/SG11201703390SA/en unknown
- 2015-10-27 KR KR1020177014414A patent/KR20170091096A/ko not_active Ceased
- 2015-10-27 JP JP2017522654A patent/JP6737781B2/ja active Active
- 2015-10-27 EP EP15854670.5A patent/EP3212290A4/en active Pending
- 2015-10-27 AU AU2015339507A patent/AU2015339507B2/en active Active
- 2015-10-27 IL IL308589A patent/IL308589A/en unknown
- 2015-10-27 HK HK18103148.5A patent/HK1244460A1/zh unknown
- 2015-10-27 UA UAA201705128A patent/UA127305C2/uk unknown
- 2015-10-27 CA CA2965151A patent/CA2965151A1/en active Pending
-
2017
- 2017-04-26 MX MX2021012047A patent/MX2021012047A/es unknown
-
2020
- 2020-07-16 JP JP2020121953A patent/JP2020180157A/ja active Pending
-
2021
- 2021-09-28 AU AU2021240153A patent/AU2021240153A1/en not_active Abandoned
-
2024
- 2024-05-29 AU AU2024203586A patent/AU2024203586A1/en active Pending